Ticker Details
MacroGenics, Inc. Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
IPO Date:	October 10, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$290.48M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.42%
Avg Daily Range (30 D):	$0.12 | 2.82%
Avg Daily Range (90 D):	$0.16 | 4.69%

Institutional Daily Volume
Avg Daily Volume:	.6M
Avg Daily Volume (30 D):	.77M
Avg Daily Volume (90 D):	1.1M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	81
Avg Trade Size (Sh.) (90 D):	114

Institutional Trades
Total Institutional Trades:	2,299
Avg Institutional Trade:	$1.68M
Avg Institutional Trade (30 D):	$2.85M
Avg Institutional Trade (90 D):	$2.85M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.74M
Avg Closing Trade (30 D):	$4.78M
Avg Closing Trade (90 D):	$4.78M
Avg Closing Volume:	118.16K

News

Feb 26, 2026 @ 10:30 PM MacroGenics to Participate in Upcoming Investor Co... Source: Na

Feb 23, 2026 @ 11:14 PM MacroGenics Announces Pausing of Enrollment of New... Source: Macrogenics, Inc.

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 14, 2025 @ 8:21 PM MacroGenics Revenue Doubles in Q2 Source: Jesterai

Feb 6, 2025 @ 7:40 PM Investigation Alert: MacroGenics, Apellis Pharmace... Source: Johnson Fistel, Llp

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.1	$-.58	$-.22
Diluted EPS	$-1.1	$-.58	$-.22
Revenue	$157.08M	$20.78M	$41.23M
Gross Profit
Net Income / Loss	$-70.36M	$-36.77M	$-14.16M
Operating Income / Loss	$-63.66M	$-33.44M	$-12.1M
Cost of Revenue			$M
Net Cash Flow	$-79.05M	$9.3M	$-22.91M
PE Ratio